日本企業においても、大日本住友製薬や中外製薬で、普及可能な再生医療の実

日本企業においても、

大日本住友製薬や中外製薬で、

普及可能な再生医療の実現に向けた動きが顕在化しており、動向に注目している。

アルツハイマー治療に関しては、バイオジェンが

BIIB037（aducanumab）のフェーズ1bデータを開示している

実際の臨床結果は、予想以上に良いものであったと評価しており、

アルツハイマー型認知症（AD）治療薬として、

初期治療で基剤となる可能性があるとみている。

BIIB037（aducanumab）の開発と販売のオプション権を持っているエーザイが、

今後どのような権利行使を行うかも焦点と考えており、

早ければ、2015年中にも

権利行使を発表する可能性があると予想している

結果 (英語) 1:

In Japan companies,Chugai, Dainippon Sumitomo PharmaAnd actualized movements toward realization of regenerative medicine that can spread, noting the trend.About Alzheimer's treatment is BiogenBIIB037 (aducanumab) Phase 1b data disclosedAnd the evaluation of actual clinical results are better than expected andAs Alzheimer's disease (AD) treatmentSuspect that could be the base material in the initial treatment.Eisai has options for development and sales of BIIB037 (aducanumab), but theFuture what exercise to do and think and focusAs early as during the year 2015Expected and is likely to announce the exercise

結果 (英語) 2:

In Japanese companies, in Dainippon Sumitomo Pharma and Chugai, movement toward the realization of dissemination possible regenerative medicine has emerged, and is focused on the trend. For Alzheimer's treatment, Biogen is a Phase 1b ​​data discloses of BIIB037 (aducanumab) actual clinical results have been evaluated as were those better than expected, as the Alzheimer's type dementia (AD) treatment , I have seen that there is a possibility that the underlying agent in the initial treatment. Eisai you have a development and sales option rights of BIIB037 (aducanumab) is, it is considered to be the focal point or make any such rights exercised future, as early as, also in 2015 year is likely to announce the exercise I'm expected to

結果 (英語) 3:

In Japan, and Japan Sumitomo, pharmaceutical, too popular movement for the realization of regenerative medicine is actualized, and pay attention to the trend. As to the treatment of Alzheimer's disease (aducanumab Biogen too BIIB 037) discloses a data of the actual phase 1 clinical results in better than expected and was evaluated, and the dementia of Alzheimer type (AD too) and there is a possibility that as a drug and early treatment and the base. TooBIIB Eisai (aducanumab 037) development and have the option to sell and what the future may be the focus and do exercise, too, as early as in 2015, and there is a possibility that the exercise of the right to expect that too